Ascendis Pharma A/S (ASND)
211.02
+2.04
(+0.98%)
USD |
NASDAQ |
Dec 29, 16:00
212.89
+1.87
(+0.89%)
After-Hours: 06:32
Ascendis Pharma Enterprise Value: 13.22B for Dec. 29, 2025
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Novo Nordisk A/S | 239.51B |
| Evaxion AS | 13.17M |
| DBV Technologies SA | 480.27M |
| Cellectis SA | 424.61M |
| Akari Therapeutics Plc | 8.919M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -71.27M |
| Revenue (Quarterly) | 249.64M |
| Total Expenses (Quarterly) | 320.91M |
| EPS Diluted (Quarterly) | -1.173 |
| Gross Profit Margin (Quarterly) | 87.87% |
| Profit Margin (Quarterly) | -28.55% |
| Earnings Yield | -2.01% |
| Normalized Earnings Yield | -2.013 |